Voleon Capital Management’s Humacyte HUMA Stock Holding History

Voleon Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-135,830	Closed	-$130K	–	847
2025 Q4	$130K	Buy	+135,830	New	+$192K	﹤0.01%	744

Other funds holding HUMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Voleon Capital Management's HUMA Position: Q1 2026 in Review

Voleon Capital Management sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 135,830 shares — an estimated $130K sold.

Voleon Capital Management first reported a position in HUMA in Q4 2025 and held it in 1 quarter. The position peaked at $130K in Q4 2025. 159 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

Voleon Capital Management reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
Voleon Capital Management sold 135,830 Humacyte shares in Q1 2026, an estimated $130K.
Voleon Capital Management first reported a position in Humacyte in Q4 2025 and held it in 1 quarter.
Voleon Capital Management's Humacyte position peaked at $130K in Q4 2025.
159 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.